Combination drugs for leukemia that has returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs for acute myeloid leukemia (AML) that has not responded to standard treatment or has returned. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 16 and 64 years old.
- You must have acute myeloid leukemia (AML) that has come back or not improved after at least one prior treatment.
- You must be generally active and able to care for yourself (ECOG score of 0-2).
- Your liver and kidney function must be within acceptable limits.
- If you could become pregnant, you need a negative pregnancy test and agree to use birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
This trial tests a combination of three drugs for treating newly diagnosed AML in older or frailer patients. The goal is to see if this combination is safe and effective, providing a gentler option for those who cannot handle standard intensive chemotherapy.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This trial tests a new combination of drugs for people with acute myeloid leukemia (AML) whose cancer did not respond to or stopped responding to the usual first-line treatment. The goal is to see if this new approach can help where the previous one didn't.
Hear when a new Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.